Welcome to our dedicated page for Genprex SEC filings (Ticker: GNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genprex, Inc. (NASDAQ: GNPX) SEC filings page on Stock Titan provides direct access to the company’s official U.S. Securities and Exchange Commission disclosures, along with AI-assisted context. As a clinical-stage gene therapy company, Genprex uses these filings to describe its oncology and diabetes pipelines, financing activities, and Nasdaq listing status.
Key documents include registration statements such as Form S-1 and Form S-3, where Genprex outlines its business overview, risk factors, and details of equity offerings and warrant structures. These filings describe the company’s focus on Reqorsa Gene Therapy (quaratusugene ozeplasmid) for non-small cell and small cell lung cancer, the Oncoprex Delivery System, and the GPX-002 diabetes gene therapy program using AAV delivery of Pdx1 and MafA genes to the pancreas.
Investors can also review Form 8-K current reports that document material events. Recent 8-Ks discuss registered direct offerings and concurrent private placements, at-the-market program updates, new patents and patent intentions around Reqorsa combinations with PD-1 and PD-L1 antibodies, additions of clinical trial sites for Acclaim-1 and Acclaim-3, and communications with Nasdaq regarding minimum bid price and stockholders’ equity requirements.
On Stock Titan, AI-powered tools summarize lengthy prospectuses and current reports, helping readers quickly identify sections related to gene therapy mechanisms, clinical trial design, regulatory designations, and capital-raising terms. As new filings appear on EDGAR, they are reflected here in near real time, giving users an organized view of Genprex’s regulatory history, financing transactions, and disclosures relevant to GNPX stock.
Genprex, Inc.’s Chief Medical Officer, Mark Stanley Berger, reported a tax-related share withholding. On February 27, 2026, 7,168 shares of common stock were withheld to cover tax obligations tied to the vesting of Restricted Stock Units granted under Genprex’s 2018 Equity Incentive Plan. After this tax-withholding disposition, he directly owned 21,692 shares of Genprex common stock.
Genprex, Inc. director and executive officer Ryan M. Confer reported a Form 4 transaction showing a tax-withholding disposition of 9,330 shares of common stock at $2.00 per share. According to the disclosure, these shares were withheld on February 27, 2026 to satisfy tax withholding obligations tied to vesting restricted stock units granted under the company’s 2018 Equity Incentive Plan. After this withholding, Confer directly holds 36,331 shares of Genprex common stock.
Genprex, Inc. reported that the Japanese Patent Office issued a favorable appeal decision to grant a patent covering use of REQORSA Gene Therapy with PD‑L1 antibodies to treat cancer, and the European Patent Office issued a decision to grant a patent for REQORSA in combination with PD‑1 antibodies. Genprex holds an exclusive license to these patents and states they strengthen protection for therapeutic combinations, including its Acclaim‑3 trial in small cell lung cancer.
The company notes it already has granted patents for REQORSA and PD‑L1 combinations in the U.S. and Korea, with a pending grant in Australia, and REQORSA and PD‑1 combinations in multiple regions including the U.S., Japan and the EU. Acclaim‑3 is a Phase 1/2 trial of REQORSA plus Genentech’s Tecentriq as maintenance therapy for extensive‑stage small cell lung cancer. The Phase 2 expansion is expected to enroll about 50 patients, with an interim analysis planned after the 25th patient has 18 weeks of follow‑up. Genprex expects to complete enrollment of the first 25 patients in the first half of 2026 and conduct the interim analysis in the second half of 2026. The trial has U.S. FDA Fast Track and Orphan Drug designations.
Genprex, Inc. received a Schedule 13G showing that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri together report beneficial ownership of 249,788 shares of Genprex common stock through warrants. This position represents 9.72% of the common stock, calculated using 2,318,894 shares outstanding as of November 19, 2025, plus the warrant shares. The warrants are subject to a 9.99% beneficial ownership blocker, limiting how many shares can be issued on exercise at any time. The investors certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Genprex.
Genprex, Inc. reported that IP Australia issued a Notice of Acceptance for its patent application covering the use of REQORSA Gene Therapy with PD-L1 antibodies to treat cancers. If granted, this patent would secure exclusivity for this drug combination in Australia and strengthen Genprex’s intellectual property portfolio alongside granted patents in the U.S. and Korea.
The company is also pursuing additional patent applications in Europe, Canada, Brazil, China and Israel and has opened a new Acclaim-3 clinical trial site at the University of Kentucky. Acclaim-3 is a Phase 1/2 trial of REQORSA plus Tecentriq as maintenance therapy for extensive stage small cell lung cancer, supported by FDA Fast Track and Orphan Drug Designations.
The Phase 2 expansion is expected to enroll about 50 patients, with an interim analysis planned after the 25th patient reaches 18 weeks of follow-up. Genprex expects to complete enrollment of these 25 patients in the first half of 2026 and conduct the interim analysis in the second half of 2026.
Genprex, Inc. reported that Nasdaq’s Hearings Panel has determined the company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of
Under Nasdaq Listing Rule 5815(d)(4)(B), Genprex will be under a mandatory panel monitor through
Genprex, Inc. filed an 8-K describing new investor presentation materials and important updates on its GPX-002 diabetes gene therapy program. The company furnished an investor deck that may be used in meetings with investors and analysts and made available on its website.
Genprex reported 2025 milestones for GPX-002, including starting preclinical research in Type 2 diabetes animal models, transferring production of GPX-002 to an experienced contract development and manufacturing organization, and submitting a request to the FDA for a meeting on its Investigational New Drug–enabling studies, described as a pivotal step toward human clinical trials. GPX-002 is being developed for both Type 1 and Type 2 diabetes, with preclinical mouse and non-human primate data showing restored or improved blood glucose control, reduced insulin requirements, higher c‑peptide levels, and improved glucose tolerance.
Genprex, Inc. reported that its Chief Medical Officer received an award of 28,500 restricted stock units (RSUs) of common stock on 12/22/2025. The RSUs were granted at a price of $0 per share under the company’s 2018 Equity Incentive Plan, as amended and restated effective June 30, 2025.
The award vests in two equal installments of 50% on February 27, 2026 and 50% on February 27, 2027, conditioned on continued service through each vesting date. Once vested, each RSU will be settled in one share of Genprex common stock. After this grant and giving effect to a 1-for-50 reverse stock split of Genprex’s common stock that was effective as of October 21, 2025, the reporting officer beneficially owns 28,860 shares of common stock.
Genprex, Inc. reported that its President, CEO and CFO, Ryan Confer, received an award of 45,000 restricted stock units (RSUs) of common stock on December 22, 2025 under the company’s 2018 Equity Incentive Plan. These RSUs vest in two equal installments of 50% on February 27, 2026 and 50% on February 27, 2027, if he continues to serve as a service provider through each vesting date. Each vested RSU will be settled in one share of Genprex common stock. Following this grant and giving effect to Genprex’s 1-for-50 reverse stock split effective as of October 21, 2025, Confer beneficially owns 45,661 shares of Genprex common stock in total.
Genprex, Inc. director Brent Longnecker reported receiving an award of 9,000 Restricted Stock Units (RSUs) of Genprex common stock on 12/22/2025 under the company’s 2018 Equity Incentive Plan. These RSUs vest 100% on the earlier of August 15, 2026 or the day before Genprex’s next annual stockholder meeting after the grant date, as long as he continues to serve as a service provider through that date. Each vested RSU will be settled in one share of Genprex common stock.
After this grant and giving effect to Genprex’s 1-for-50 reverse stock split effective as of October 21, 2025, Longnecker beneficially owns 9,165 shares of common stock directly and 10 shares indirectly through Longnecker Associates Ltd.